Linehan, W MarstonSpellman, Paul TRicketts, Christopher JCreighton, Chad JFei, Suzanne SDavis, CalebWheeler, David AMurray, Bradley ASchmidt, LauraVocke, Cathy D
...
Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted...
Brat, Daniel JVerhaak, Roel G WAldape, Kenneth DYung, W K AlfredSalama, Sofie RCooper, Lee A DRheinbay, EstherMiller, C RyanVitucci, MarkMorozova, Olena
...
The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutatio...
